
Verismo Therapeutics: Pioneering enhanced T-cell immunotherapy for hard-to-treat cancers.
Verismo Therapeutics, founded with a mission to revolutionize cancer treatment, focuses on developing advanced chimeric antigen receptors (CARs) to enhance T-cell-based immunotherapy, particularly for solid tumors and non-hematologic malignancies. Their flagship technology, the KIR-CAR platform, aims to reduce T-cell exhaustion and improve efficacy in killing solid tumor cells, addressing a significant gap in current cancer therapies.
Notable figures affiliated with Verismo Therapeutics include leading scientists and industry experts in cellular immunotherapy. The company has garnered attention from prominent investors in the biotech sector. Key achievements include successful in vivo studies demonstrating the effectiveness of their KIR-CAR construct. Verismo's innovative approach has the potential to significantly impact cancer treatment paradigms, offering new hope for patients with hard-to-treat cancers.

Verseau Therapeutics
verseautx.com

Immpact Bio
immpact-bio.com

CERo Therapeutics
cero.bio

A2 Biotherapeutics
a2bio.com

AffyImmune Therapeutics
affyimmune.com

Chimera Bioengineering
chimera.bio

Affini-T Therapeutics
affinittx.com

Inceptor Bio
inceptor.bio

Veru
verupharma.com
Virsti Therapeutics

Carisma Therapeutics
carismatx.com

Tactiva Therapeutics

Telo Therapeutics

Verastem

Allogene Therapeutics
allogene.com
Companies similar to Verismo Therapeutics include Verseau Therapeutics, Immpact Bio, CERo Therapeutics and A2 Biotherapeutics.
Verismo Therapeutics was founded in 2020.
Verismo Therapeutics' headquarters is located in Philadelphia, PA, US.
Verismo Therapeutics' most recent funding round was for $17M (USD) in July 2023.
As of Jul 18, 2023, Verismo Therapeutics has raised a total of $40M (USD).
Verismo Therapeutics has 14 employees as of Feb 5, 2024.